European AIDS Treatment Group·2 min read·medium
[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus
H
https://www.facebook.com/EuropeanAIDSTreatmentGroup![[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus](/api/imagekit?u=https%3A%2F%2Fwww.eatg.org%2Fwp-content%2Fuploads%2F2025%2F03%2Fclinical-trial-icon-gaac45ea20-1280.png&w=3840&q=75){kind=icon}
✦AI Summary
Atea Pharmaceuticals has launched a Phase 1 clinical trial for AT-587, an oral antiviral drug designed to treat hepatitis E. The study aims to assess the safety and pharmacokinetics of the drug in healthy volunteers.
Atea Pharmaceuticals, Inc. announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus (HEV) infection.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in